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Abstract
Preclinical studies support the therapeutic potential of histone deacetylases inhibitors (HDACi) in combination with taxanes.
The efficacy of combination has been mainly ascribed to a cooperative effect on microtubule stabilization following tubulin
acetylation. In the present study we investigated the effect of paclitaxel in combination with two novel HDACi, ST2782 or
ST3595, able to induce p53 and tubulin hyperacetylation. A synergistic effect of the paclitaxel/ST2782 (or ST3595)
combination was found in wild-type p53 ovarian carcinoma cells, but not in a p53 mutant subline, in spite of a marked
tubulin acetylation. Such a synergistic interaction was confirmed in additional human solid tumor cell lines harboring wild-
type p53 but not in those expressing mutant or null p53. In addition, a synergistic cytotoxic effect was found when ST2782
was combined with the depolymerising agent vinorelbine. In contrast to SAHA, which was substantially less effective in
sensitizing cells to paclitaxel-induced apoptosis, ST2782 prevented up-regulation of p21
WAF1/Cip1 by paclitaxel, which has a
protective role in response to taxanes, and caused p53 down-regulation, acetylation and mitochondrial localization of
acetylated p53. The synergistic antitumor effects of the paclitaxel/ST3595 combination were confirmed in two tumor
xenograft models. Our results support the relevance of p53 modulation as a major determinant of the synergistic interaction
observed between paclitaxel and novel HDACi and emphasize the therapeutic interest of this combination.
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Introduction
Epigenetic modifications and deregulation of gene expression
have been linked to the development of malignant phenotype and
tumor progression, likely as a consequence of aberrant silencing of
multipletumor suppressorgenes[1].The dynamicprocess of histone
acetylation, regulated by the balance action of histone acetyltrans-
ferases (HAT) and deacetylases (HDAC), plays a critical role in
modulation of gene expression [2,3]. HDAC inhibitors (HDACi)
represent a promising class of antitumor agents which have been
developed to reverse the silencing of critical regulatory pathways
[4,5]. Indeed, the cellular response to treatment with HDACi shows
pleiotropic effects involving cell cycle arrest, induction of apoptosis
and differentiation, modulation of microtubule function, DNA
repair, and angiogenesis [4,6,7]. Based on these effects and, in
particular, the activation of proapoptotic pathways, HDACi may
have interest in combination with conventional chemotherapeutic
agents to enhance tumor cell chemosensitivity [8,9]. However, given
the different isoenzyme specificity of the available HDACi, the
rational use of their combination remains to be defined, because the
specific role of the individual HDAC isoenzymes as therapeutic
targets has not been clearly established [10,11].
In addition to the transcriptional effects, HDACi are also
involved in acetylation status of non-histone proteins implicated in
critical regulatory processes (e.g., tubulin and transcription factors)
[12,13]. Recently, we have reported that HDACi of a novel series
were very effective in inducing p53 and tubulin acetylation [14].
Since tubulin acetylation is expected to favour microtubule
stabilization [15,16], which is recognized as a primary mechanism
of action of taxanes [17], the present study was designed to explore
the cellular/molecular basis of the interaction between paclitaxel
and selected HDACi of the novel series [14]. Indeed, several
studies have shown that the pan-HDACi SAHA enhances the
growth inhibitory effect induced by paclitaxel against various
human tumor cells [18–21]. In the present study we found that, in
contrast to SAHA, novel HDACi (ST2785 and ST3595) and
paclitaxel synergistically inhibit the proliferation of ovarian
carcinoma cells with wild-type p53, and dramatically activated
apoptosis. Similar results were observed by combining ST2782
with the microtubule depolymerising agent vinorelbine. In
addition, experimental evidence we obtained in a panel of human
solid tumor cell lines characterized by a different p53 gene status
supports the implication of modulation of wild-type p53 in
mediating the synergistic effect of the PTX/ST2782 (or ST3595)
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in wild-type p53 tumor xenograft models.
Materials and Methods
Drugs and antibodies
ST2782 (N-hydroxy-3-(49-hydroxybiphenyl-4-yl)-acrylamide, al-
so known as RC307) and ST3595 were prepared as previously
described [14]. SAHA was provided by BIOMOL International LP
(Plymouth Meeting, PA). Paclitaxel (PTX, Indena, Milan, Italy),
nocodazole (Calbiochem EMD Chemicals, Inc., La Jolla, CA) and
ST2782 were dissolved in dimethyl sulfoxide (DMSO); vinorelbine
(Pierre Fabre, Castres, France) was dissolved in H2O. In all
experiments the highest final concentration of DMSO in culture
medium was0.5%. For invivostudies, ST3595,ST2782 and SAHA
were dissolved in a mixture of DMSO and cremophor, suspended in
sterile, distilled water (10+5+85%) and delivered orally. PTX was
dissolved in a mixture of ethanol and cremophor (50+50%)
employing a magnetic stirrer and stored at 4uC. Before treatment,
the drug was diluted in saline (10% of ethanol-cremophor). After
dilution, the drug was kept in ice and administered i.v.
We used primary antibodies against p53 (Dako, Glostrup,
Denmark); p21
WAF1/Cip1 (Neomarker, Union City, CA); caspase-3
(CPP32), cleaved caspase-3 (Asp
175), acetylated p53 (lys
382) (Cell
Signalling Technology, Beverly, MA); PARP-1 (Oncogene Sci-
ence, Uniondale, NY); cytochrome C (BD Pharmingen, Becton
Dickinson, Franklin Lakes, NJ); actin, acetylated tubulin and b-
tubulin (Sigma, St. Louis, MO); mitotic protein monoclonal 2
(MPM-2) (Upstate Biotechnology, Lake Placid, NY); Raf-1 (sc-
7267), cyclin-B1 (sc-245), cdc-25C (sc-327) (Santa Cruz Biotech-
nology, Santa Cruz, CA); mitochondrial marker (Abcam, Cam-
bridge, UK); topoisomerase II (Transduction Laboratories,
Lexington).
Cell culture and antiproliferative activity
The following human cell lines: IGROV-1 [22] ovarian
carcinoma and its cisplatin resistant subline IGROV-1/Pt1,
selected by exposure to increasing drug concentrations [22],
H460 human non-small cell lung cancer [23], HCT116
colonrectal adenocarcinoma cell line [24], and SAOS osteosarco-
ma [25] were maintained in RPMI 1640 (Lonza, Verviers,
Belgium) supplemented with 10% FBS (Invitrogen, Carlsbad, CA).
The U2OS osteosarcoma cell line [26] were cultured in McCoy’s
(Lonza) supplemented with 10% FBS (Invitrogen). After 24 h, cells
were exposed to ST2782 or to ST3595 to antimicrotubule agent
or to their combination for 72 h. After treatment, adherent cells
were trypsinized and counted by a cell counter (Coulter
Electronics, Luton, UK). Drug interactions were analyzed using
CalcuSyn software (Biosoft), which calculates the median effect
dose, Dm (analogous to the IC50), of the drug combinations using
the median effect equation. Analysis of drug interaction to
determine the combination index (CI) was based on the multiple
drug effect equation of Chou and Talalay [27]. CI=1 indicates an
additive effect; ,1 synergy, .1 antagonism.
Cell cycle analysis
Cell cycle perturbations were analyzed at different times after the
end of treatment, as described previously [28], by flow cytometry
(FACScan, Becton Dickinson) using CellQuest Software.
Dual parameter analysis flow cytometry (cell cycle and
apoptosis induction)
Cells were fixed in 1% paraformaldeyde for 30 min in ice and,
after the removal of the fixative, they were permeabilized in 70%
ice cold ethanol for 30 min. After suspension in PBA (PBS
containing 0.1% Tween-20 and 1% BSA), cells were incubated
with a rabbit polyclonal anti-cleaved caspase 3 antibody (CPP32,
diluted 1:500 in PBA, Cell Signaling) for 1 hour, washed twice
with PBA solution and then incubated with an anti-rabbit-Alexa
Fluor 488 (1:500, Invitrogen). Cells were counterstained with
propidium iodide for 1 hour and then a dual parameter analysis
was performed by FACScalibur (Becton Dickinson). The green
FITC-fluorescence, expressed on a logarithmic scale, indicated the
CPP32 cleaved form. The PI-red fluorescence, was taken as index
of DNA content.
Assessment of apoptosis and mitotic cells
Apoptosis was detected by TUNEL assay, using the in situ Cell
Death Detection Kit fluorescein (Roche, Germany). Apoptosis was
assessed by FACScan, and the results were analyzed using the
CellQuest software. To detect MPM-2 immunoreactivity, cells
were processed as described previously [29] and examined by
fluorescence microscopy. The number of mitotic cells was assessed
on at least 300 cells in two different smears and referred to the
whole cell population (floating and adherent cells).
Western-blot analysis
Cells were lysed as previously described [30]. The filters were
incubated with primary antibodies and with peroxidase-conjugat-
ed secondary antibodies. Immunoreactive bands were revealed by
using the enhanced chemiluminescence detection system from
Amersham Biosciences (Piscataway, NJ).
Tubulin polymerization assay
Cells were exposed to drugs and, 24 h later, processed for the
tubulin polymerization assay. Samples were prepared as described
by Blagosklonny et al. [17] and Lanzi et al. [29] and separated by
SDS-PAGE (10% resolving gel and 3% stacking gel), and tubulin
distribution was assessed by immunoblot analysis using a mouse
anti–b-tubulin antibody (Sigma).
Analysis of cytochrome C release and subcellular
fractionation
Following treatment with single agents (IC50) or their combi-
nation, IGROV-1 cells were processed as described previously
[28]. Cytosolic and mitochondrial fractions were analyzed by
immunoblot analysis. In immunoblots, mouse monoclonal anti-
mitochondrial marker (Abcam) and anti-topoisomerase II (Trans-
duction Laboratories) antibodies were used as mitochondrial and
nuclear markers, respectively.
Small interfering RNA transfection
Small interfering RNAs were synthesized by Invitrogen Corp.
(Carlsbad, CA). The p53-siRNA consisted of a mixture of two
siRNA duplexes targeting different regions of the p53 mRNA
(Validated stealth RNAi DuoPak). As a negative control, Medium
GC Duplex of StealthH RNAi Negative Control Duplexes
(Invitrogen) was used. Transfection of cells with siRNA duplexes
was performed using Lipofectamine 2000 Reagent (Invitrogen).
IGROV-1 cells were transfected with control siRNA or p53-
siRNA at a final concentration of 100 nM for 24 h. After
silencing, cells were replaced and treated with drugs on the
second day as indicated. Gene silencing effects were monitored by
Western blot also on the day of the treatment.
In vivo antitumor activity
Female athymic Swiss nude mice (7–10 weeks-old, Charles
River, Calco, Italy). Were maintained in laminar flow rooms
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approved by the Ethical Committee for Animal Experimentation
of the Fondazione IRCCS Istituto Nazionale Tumori (Internal
reference INT_21/09 approved on 21 October 2009 Sent to
Ministry of Health on 9 December 2009) according to the Italian
law DL 116/92. The IGROV-1 human ovarian carcinoma was
established as i.p. growing tumor xenograft [31]. Ascitic cells
(2.5610
6) suspended in 0.2 ml saline were inoculated s.c. in both
flanks of each animal. Following s.c. injection of exponentially
growing U2OS osteosarcoma cells (10
7 cells/0.2 ml saline). The
tumor line was achieved by serial s.c. passages of fragments
(about 36363 mm). Groups of four mice bearing bilateral s.c.
tumors were employed. PTX was delivered every fourth day for
four times (q4dx4). HDACi were given qdx5/wx3w. Tumor
growth was followed by biweekly measurements of tumor
diameters with a Vernier caliper. Tumor volume (TV) was
calculated according to the formula: TV (mm
3)=d
2xD/2, where
d and D are the shortest and the longest diameter, respectively.
Treatment started when TV was less of 100 mm
3. The efficacy of
the drug treatment was assessed as: i) Tumor volume inhibition
percentage (TVI%) in treated versus control mice, calculated as:
TVI%=100-(mean TV treated/mean TV control x 100); ii)
Complete regression (CR), i.e. disappearance of the tumor lasting
at least 10 days. The toxicity of the drug treatment was
determined as body weight loss and lethal toxicity. Deaths
occurring in treated mice before the death of the first control
mouse were ascribed to toxic effects. Student t test (two tailed)
and Fisher’s exact test were used for statistical comparison of
tumor volumes and CR, respectively.
Results
Cell growth inhibition studies
The combination of ST2782 with PTX (IC20 and IC50,
corresponding to drug concentrations producing 20% and 50%
of cell growth inhibition assessed by dose-response curves after
72 h exposure) resulted in a marked growth inhibition of IGROV-
1 cells when compared to single agents (Figure 1A). The
sensitization was also evident at low concentrations of ST2782,
which alone caused negligible effects. The analysis of drug
interaction by Chou and Talalay method supported a synergistic
interaction between PTX and ST2782 (Figure 1A). A similar
interaction was found with a closely related analog, ST3595
(Figure 1B). Again, ST2782 enhanced the growth inhibition also of
microtubule-destabilizing agents, including vinblastine and noco-
dazole (Figure 1C). The potentiation of PTX effect by ST2782 was
less evident in p53 mutant IGROV-1/Pt1 subline, characterized
by a hypersensitivity to PTX because of mutational inactivation of
p53 (Figure 1A). Under the same conditions, the combination
treatment of PTX with SAHA, a known pan-HDACi currently
used in clinical therapy, resulted in addictive effects in IGROV-1
cells (Figure 1D).
To explore the relevance of p53 gene status in the synergistic
interactions between PTX and the two novel HDACi, we
determined the antiproliferative effect of the drug combinations
in a panel of human solid tumor cell lines harboring wild-type,
mutant or null p53 (Table S1). A synergistic cytotoxic interaction
between PTX and ST2782 was found in cell systems expressing
wild-type p53 (H460 and HCT116) but not in those carrying a
mutant (A431) or null (SAOS) p53. In addition, a moderate
synergistic activity of the PTX/ST3595 combination was found in
a wild-type p53 U2OS cell model of mesenchymal origin
(osteosarcoma) (Table S1).
Cell-cycle perturbation and analysis of the cellular
morphology
To investigate the cellular basis of the synergistic effects, we
examined the cell cycle perturbation of IGROV-1 cells exposed to
ST2782 or its combination with PTX or vinorelbine. At low
concentrations (IC50), PTX induced cell accumulation in G2/M
phase (Figure 2A). On the contrary, ST2782 alone produced a
marginal perturbation of cell-cycle progression. The concomitant
exposure to both drugs determined an increase of G2/M phase
arrest and appearance of cells in sub-G1 phase, thus suggesting the
induction of cell death. This effect was still evident at a low non-
toxic concentration of ST2782 (3 mM). After 24 h of treatment,
the morphological analysis of MPM-2 immunoreactivity in cells
treated with the combination evidenced a decrease in the
percentage of mitotic cells in both cell lines as compared to
PTX alone, supporting a G2 phase arrest with a concomitant
increase of the apoptotic cells (Figure 2B). Similar effects were
found also following treatment with vinorelbine (Figure 2C) and
nocodazole (data not shown). Additional biochemical investiga-
tions in cells treated with the ST2782/PTX combination were
performed to support cell cycle arrest in G2 phase. In IGROV-1
cells exposed for 24 h to the PTX/ST2782 combination, using
IC80 concentrations for each agent, the G2 arrest was confirmed
by the decrease of mitosis-specific phosphorylated epitopes
recognized by MPM-2 antibody, lack of phosphorylation of Raf-
1, Bcl-2 and cdc25C, clearly detected by loss of mobility shift, and
reduced level of cyclin B1 as compared to PTX alone (Figure 2D).
Moreover, under the same conditions, the combined treatment
resulted in increased caspase 3 (CPP32) activation associated with
cleavage of PARP-1, according to the synergistic effects observed
in cell growth experiments (Figure 1).
Sensitization to apoptosis by PTX/ST2782 combination
We tested the hypothesis that the sensitization effect of ST2782
was related to enhanced cell susceptibility to antimicrotubule
agent–induced apoptosis. Under the same treatment conditions
used for the analysis of cell-cycle perturbation, exposure to each
single agent resulted in a barely detectable CPP32 activation in
IGROV-1 cells, thus indicating that, at the tested concentrations
(IC50), the effect of single-drug treatment was predominantly
cytostatic (Figure 3). In contrast, IGROV-1 cells treated with the
drug combination exhibited a dose-dependent activation of
CPP32, associated with cleavage of PARP-1, which was already
detectable after 24 h (Figure 3A). Moreover, consistent with an
enhanced activation of caspase-dependent apoptotic pathways, the
PTX/ST2782 combination caused the cytosolic release of
cytochrome C, a caspase activator, which was associated to a
decrease in the mitochondrial cytochrome C content. A weak
CCP32 activation and cytosolic release of cytochrome C were
found in the IGROV-1/Pt1 cell lines. The analysis of apoptosis,
determined by TUNEL assay (Figure 3B), revealed a marginal (if
any) induction of apoptosis in the presence of each single agent
after 72 h exposure. On the contrary, the combined treatment
produced a remarkable increase of apoptosis only in IGROV-1
cells (Figure 3B). SAHA combined with PTX induced a lower
appearance of apoptotic cells as compared to the combination of
PTX and ST2782 (Figure 3B), according to a marginal
sensitization observed in cell growth inhibition experiments
(Figure 1D) and to a slight induction of CPP32 and PARP-1
cleavage (Figure 3C). A cytosolic release of cytochrome C with a
weak decrease in the mitochondrial cytochrome C content was
found after 48 h exposure to SAHA/PTX combined treatment in
IGROV-1 cells (figure 3D). When combined with vinorelbine,
ST2782 induced the cleavage of CPP32 in IGROV-1 cells
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PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e29085Figure 1. Antiproliferative effects of ST2782 alone (&) or in combination with PTX (A) or vinorelbine (C, VIN) or nocodazole (C,
NCD) at two indicated concentrations corresponding to IC20 (.)o rI C 50 (m), against ovarian carcinoma cells treated for 72 h. Similar
experiments were performed with the combination of PTX/ST3595 (B) or PTX/SAHA (D). Each point of the dose-response curves is the mean6SD of
three independent experiments. Each panel reports the combination index values (CI) calculated according to ‘‘Chou Talalay method’’.
doi:10.1371/journal.pone.0029085.g001
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PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e29085Figure 2. Effect of ST2782 or antimicrotubule agents alone or their combination on cell cycle distribution (A) or apoptosis and
mitosis (B and C) in IGROV-1 and IGROV-1/Pt1 cells. (A) FACS analysis of the cell cycle perturbation. Cells were treated for different times with
subtoxic (antiproliferative) concentrations of ST2782 (10 and 3 mM) combined with PTX at IC50 (0.12 mM). B) and C) Apoptosis, determined by TUNEL
assay and assessed by FACScan, and mitotic index, determined by MPM-2 staining and fluorescence microscopy analysis, in cells exposed for 24 h to
IC50 of PTX (0.12 mM and 0.012 mM, for IGROV-1 and IGROV-1/Pt cells, respectively) or vinorelbine (0.047 mM) or ST2782 (10 mM) or their combination.
The data, expressed as percent of total cell population, are the mean6SD of three independent experiments. Data were analyzed by t test (control vs
treatment): *P,0.05, **P,0.005. D) Activation of mitosis-related factors in IGROV-1 cells exposed to cytotoxic concentrations of ST2782 (20 mM) and
PTX (1.2 mM). Western blot analysis of cell lysates was performed at the end of treatment (24 h). Actin is shown as a control for protein loading. The
size of caspase 3 (CPP32) and of its cleavage products is indicated.
doi:10.1371/journal.pone.0029085.g002
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protein, consistent with the synergistic cytotoxic effect of the
combination (Figure 1B).
Since in A431 cells expressing a mutant p53, an antagonistic
effect of the ST2782/PTX combination was observed (Table S1),
we analyzed the activation status of CPP32 in these cells following
exposure to low concentrations (IC50) of both drugs (Figure 3F).
Results indicated that PTX alone induced a weak CPP32
activation after 48 h of treatment, that was not enhanced by
combination with ST2782.
To investigate the interrelationship between cell cycle modula-
tion and apoptosis induction, we have explored whether changes
in cell cycle triggered by HDACi resulted in increased induction of
apoptosis (Figure S1). IGROV-1 cells were stained with an
antibody specific for cleaved-CPP32 and Alexa 488 anti-rabbit
antibody. Cells were counterstained with propidium iodide to
determine DNA content. At low concentrations (IC50), single-
agent treatment with PTX or with ST2782 did not induce
cleavage of CPP32 at any time considered. Conversely, after 24 h
of combined treatment, we found the appearance of the CPP32
cleaved-positive cells with a DNA content corresponding to that of
G2/M phase. Moreover, at longer exposure times (48 and 72 h),
CPP32-cleaved positive cells were found in all cell cycle phases.
a-tubulin acetylation
We have previously documented that ST2782 induces hyper-
acetylation of a-tubulin [14]. Since also PTX induces increase of
a-tubulin acetylation, we have investigated the drug effects on the
microtubule system of cells treated for 24 h with PTX (IC50)o r
with ST2782 (IC50) alone or in combination (Figure 4). Tubulin
acetylation was detectable only in polymerized form of PTX-
treated cells, whereas ST2782 induced a-tubulin acetylation in
both soluble and polymerized form. The PTX/ST2782 combi-
nation markedly enhanced the acetylation of polymerized a-
tubulin (Figure 4A). The analysis of the status of a-tubulin
acetylation in whole cellular extract of IGROV-1 and IGROV-1/
Pt1 evidenced a comparable increase of the acetylated form of a-
tubulin (Figure 4B).
Expression of p53 and p21
WAF1/Cip1
Since the transcriptional activity of p53 has a protective role in
response to mitotic spindle damage [28], we have investigated the
drug effects on p53 expression, following treatment with PTX,
ST2782 alone or their combination for 24 and 48 h, at doses
corresponding to IC50 (Figure 5A) or IC80 (Figure 5B). PTX itself
was found to induce up-regulation of p53 in IGROV-1 cells but
not in the p53 mutant subline, IGROV-1/Pt1 and in p53 mutant
A431 cell lines (Figure 5C, D). ST2782 alone, at the low
concentration (IC50), induced a slight down-regulation of p53
expression (Figure 5A) and prevented the PTX-induced p53 up-
regulation. Under these conditions, ST2782/PTX combination
markedly enhanced acetylation of p53 at 24 h. p53 modulation
induced by the combination, still detectable at 48 h, was
associated with a prevention of p21
WAF1/Cip1 up-regulation
induced by PTX in IGROV-1 cells (Figure 5A and B). Higher
concentrations of ST2782 (IC80), which caused p53 acetylation,
also induced a marked down-regulation of p53 (Figure 5B).
IGROV-1/Pt1 and A431 cells did not show significant modula-
tion of acetylated p53 and downregulation of p21
WAF1/Cip1
following treatment with PTX/ST2782 in comparison to PTX
alone (Figure 5C and D).
The role of p53 acetylation in mediating the synergistic
cytotoxic interaction in IGROV-1 cells was also investigated
ST2782/vinorelbine combination (Figure 5E). After 48 h of
combined treatment with low concentrations (IC50) of both drugs,
cells showed a slight enhancement in the level of p53 acetylation
compared to that observed following exposure to vinorelbine
alone. In addition, ST2782 was able to prevent the up-regulation
of p53 and p21
WAF1/Cip1 induced by the microtubule depolymer-
ising agent (Figure 5E).
To better understand the role of p53 in cellular response, we
investigated the effects of the single agents and their combination
in IGROV-1 cells following p53 down-regulation by siRNA
(Figure 5F). As expected, following p53 silencing, cells exhibited an
increased sensitivity to PTX (IC50, 0.2260.12 mM in negative
control cells versus 0.0660.025 mM in p53-siRNA transfected
cells), as also indicated by caspase activation (Figure 5F). However,
in spite of an increased sensitivity to ST2782 itself (IC50,
6.1261.9 mM in negative control cells versus 3.561.1 mMi n
p53-siRNA transfected cells), no synergistic interaction was
evident in the combination (Figure 5F).
Since SAHA was less effective in sensitizing cells to PTX-
induced apoptosis, we explored p53 and p21
WAF1/Cip1 modulation
by the SAHA/PTX combination (Figure 5G). When compared to
PTX alone, no appreciable modulation of p53 and p21
WAF1/Cip1
was detected, thus providing a further indirect support to the
implication of p53 in the synergistic interaction between ST2782
and PTX. Relevant to this point is the observation that p53 was
acetylated following exposure to ST2782 and ST3595 (a methoxy
derivative of ST2782), but barely (if any) following exposure to
SAHA (Figure 5H).
Since recent studies support a role of acetylated p53 in the
transcription-independent regulation of apoptosis involving p53
translocation to mitochondria in stressed cells [32,33], we
examined the subcellular localization of p53 following 24 h-
exposure to the drugs (Figure 6). The combination of ST2782 with
PTX, at the IC50 concentrations, induced a substantial translo-
cation of acetylated p53 to mitochondria (Figure 6A). This
subcellular distribution was associated with a concomitant release
of cytochrome C (Figure 3). The combination of SAHA with PTX
induced a lower extent of mitochondrial translocation of
acetylated p53. ST2782 induced a marked down-regulation of
the mutant p53 in IGROV-1/Pt1 (Figure 6B), barely detectable in
the mitochondrial fraction.
In vivo antitumor activity
The antitumor efficacy of the combination of HDACi with PTX
was investigated in the IGROV-1 ovarian carcinoma xenograft
established with the same cell system used in cellular studies and in
a different model (U2OS osteosarcoma) to explore whether the
synergistic interaction may have a broad therapeutic interest, using
well-tolerated doses of PTX (i.e., around K MTD), with the
intermittent i.v. treatment schedule (usually q4dx4), and of
HDACi (100 mg/kg), with daily oral administration. Experiments
performed with ST2782/PTX and ST3595/PTX combinations
indicated an appreciable improvement of the antitumor efficacy
over the single-agent therapy (Table 1). However, the therapeutic
effects of ST3595 (a methoxy derivative of ST2782) were more
consistent, likely as a consequence of a more favourable oral
bioavailability and pharmacological profile (in particular, meta-
bolic stability). Therefore, further in vivo experiments were
performed with the methoxy analog. In contrast to ST3595,
SAHA at the same dose was not effective in modulating the PTX
activity, but it markedly worsened the toxicity of the combination
(Table 1). The improved efficacy of ST3595/PTX combination
over SAHA/PTX was dramatically evidenced in the human
osteosarcoma U2OS, a model carrying wild-type p53 (Figure 7).
ST3595 in combination with the taxane produced complete tumor
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PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e29085Figure 3. Induction of apoptosis and analysis of apoptosis-related factors in IGROV-1 and IGROV-1/Pt1 and A431 cells exposed to
the IC50 PTX or vinorelbine (VIN) or ST2782 (ST) or SAHA or their combination. A) Cleavage of caspase 3 (CPP32) and PARP-1 and
cytochrome C release. Western blot analysis was performed after 24 h exposure to drug concentrations used in experiments of Fig. 2A. b-Tubulin is
shown as a control of protein loading. Release of cytochrome C was examined in cytosolic and mitochondrial extracts, prepared after 24 h exposure.
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experiment) in all animals treated, without relevant manifestations
of toxicity. In contrast, SAHA did not enhance the PTX efficacy
but caused an appreciable increase of toxicity as evidenced by a
marked body weight loss of animals treated with the combination.
Discussion
As observed for most target-specific agents, single-agent therapy
with HDACi may not be sufficiently efficient to control tumor
growth in the majority of solid tumors in spite of the claimed
selectivity for tumor cells. It is now evident that, given the
pleiotropic effects of HDACi, their therapeutic potential is
expected to be best exploited through combination with other
antitumor agents [8,9]. Indeed preclinical data with several tumor
cell lines have shown synergistic effects when combining HDACi
with various antitumor therapies [34–38]. The potentiation of the
killing effects of DNA damaging agents could reflect modulation of
DNA damage response [38]. In general, the ability of HDACi to
enhance drug-induced cytotoxicity has been related to activation
of proapoptotic pathways [7,8].
The antitumor effects of HDACi have been at least in part
related to modulation of chromatin structure and gene expression
resulting in reactivation of silenced genes. In addition to
modulation of transcription, the biological effects of HDACi
may be mediated by acetylation of nonhistone proteins, including
transcription factors (e.g., p53), and by functional alterations of
critical proteins (e.g., tubulin and Hsp90) [15,16,39] The latter
effects, which involve the inhibition of the cytoplasmatically
localized HDAC6 isoform [15,16,40,41], have been exploited to
achieve a synergistic interaction between pan-HDACi and taxanes
[21]. The antitumor efficacy of HDACi/PTX has been ascribed to
cooperative effects on microtubule stabilization mediated by
tubulin acetylation [21]. Based on this hypothesis, we have
examined in ovarian carcinoma cells the interaction of paclitaxel
with novel HDACi endowed with ability to induce hyperacetyla-
tion of p53 and a-tubulin. Our results show that the combination
of the novel HDACi (ST2782 or ST3595) with PTX had a
synergistic effect only in the IGROV-1 cells carrying wild-type
p53, but not in the p53 mutant platinum-resistant subline
IGROV-1/Pt1 in spite of a similar drug effect on a-tubulin
acetylation. A synergistic activity of PTX combined with the two
novel HDACi (ST2782 and ST3595) was also observed in
additional tumor cell lines, H460, HCT116 and U2OS, expressing
wild-type p53. Conversely, an antagonistic interaction was found
in SAOS and A431 cell lines that harbor null and mutated p53,
respectively. Moreover, in IGROV-1 cells a synergistic effect was
found also with the combination of ST2782 and vinorelbine, a
known microtubule destabilizing agent. These observations do not
support a primary role of tubulin acetylation and polymerization
in the synergistic effect of the combination.
The finding that the synergistic effects was produced by the
combination only in wild-type p53 cells suggested the implication
of functional p53 as a critical determinant of drug interaction. In
Figure 4. Analysis of the tubulin polymerization status in IGROV-1 cells on extracts derived by cell fractionation (A) or by lysis of
whole cells (B). Cells were exposed to ST2782 (ST, 10 mM), PTX (0.1 mM) alone or their combination for 24 h. Cell fractionation was performed as
indicated in the Materials and Methods section. Soluble cytosolic (S) or polymerized (P) a-tubulin was detected in cell fractions by Western blot
analysis.
doi:10.1371/journal.pone.0029085.g004
B) Apoptosis determined by TUNEL assay after 72 h of treatment (ST2782 10 mM, PTX 1.2 mM and SAHA 10 mM). The percentages of TUNEL-positive
cells are indicated in each panel. One representative experiment of at least three is shown. The results, expressed as percentage of TUNEL-positive
cells, represent the mean6SD of three independent experiments. C) Cleavage of CPP32 and PARP-1 in IGROV-1 cells treated with SAHA and/or PTX to
the same concentrations used for TUNEL assay. D) Analysis of cytochrome C release in cytosol and in mitochondrial extract prepared after 48 h
exposure to PTX or SAHA alone or their combination in IGROV-1 cells. E) Cleavage of CPP32 and PARP-1 in IGROV-1 cells treated with vinorelbine
(0.047 mM) or ST2782 (10 mM) alone or in combination. F) Cleavage of CPP32 in A431 cells treated with ST2782 (ST, 3 mM) or PTX (0.0035 mM) alone or
in combination. b-Tubulin is shown as a control of protein loading when whole-cell lysates are used. The size of CPP32 and of their cleavage products
are indicated. An antibody against a mitochondrial marker and an antibody against actin were used as protein control to ensure a correct subcellular
fractionation process.
doi:10.1371/journal.pone.0029085.g003
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WAF1/Cip1. A) IGROV-1 cells were treated for 24 and 48 h with PTX (0.12 mM) or
ST2782 (ST, 10 mM). B) IGROV-1 cells were exposed to a cytotoxic doses (IC80) of ST2782 (20 mM) and/or paclitaxel (1 mM) for 24 hours. C) IGROV-1/Pt1
cells were treated with PTX (0.012 mM) or ST2782 (ST, 10 mM) for 24 and 48 hours. D) A431 cells were treated with PTX (0.0035 mM) or ST2782 (ST,
3 mM) for 24 h and 48 h. E) IGROV-1 cells were exposed to ST2782 (10 mM) and vinorelbine alone (0.047 mM) or in combination for 48 h. F) Effects of
PTX (0.12 mM) and its combination with ST2782 (10 mM) in IGROV-1-negative control cells and in p53-siRNA–transfected cells. The negative control
cells are referred to cells transfected with RNAi-negative control duplex containing 48% GC. Actin is shown as a control of protein loading. Panel
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with a partial p53 down-regulation and acetylation of the residual
p53 protein. The acetylated form of p53 was found to be localized
predominantly in mitochondria, where it may play a transcription-
independent proapoptotic activity [32,33].
Our previous studies support a protective role of the transcrip-
tional activity of p53 in response to mitotic spindle damage [28].
Down-regulation of p53 could result in a sensitization to PTX as a
consequence of prevention of p21
WAF1/Cip1 inductionin response to
PTX. Indeed, we have found that ovarian carcinoma cells selected
for resistance to cisplatin and characterized by mutational
inactivation of p53 are hypersensitive to PTX [42]. The results
presented in this study indicated that ST2782 prevented the up-
regulation of p21
WAF1/Cip1 induced by both PTX, a microtubule
polymerising agent and vinorelbine, a microtubule depolymerising
agent. The modulation of p21
WAF1/Cip1 expression in PTX-treated
cells by ST2782 is reminiscent of the effect of pifithrin-a,a
transcriptional inhibitor of p53 [24]. Relevant to this point is the
observation that, in contrast to SAHA, ST2782 and ST3595
induced a dose-dependent down-regulation of p53. The mechanism
of this effect is not clearly understood, but likely it is related to
modulation of acetylation status of Hsp90, which, as is a protein
substrate for the cytoplasmic HDAC6 isoenzyme, may be involved
in p53 stabilization [39,43,44].
Figure 6. Analysis of mitochondrial p53 translocation induced by ST2782 or SAHA in absence or presence of PTX in IGROV-1 and
IGROV-1/Pt1 cells. The cytosolic and mitochondrial extracts were prepared after 24 h of treatment with PTX alone or combined with HDACi. An
antibody against a mitochondrial marker and an antibody against topoisomerase II were used as protein control to ensure a correct subcellular
fractionation process. A nuclear extract (n.e.) was used as a positive control for topoisomerase II. A) Comparison of the p53 localization in cytosol or
mitochondrial fraction after the combination of PTX (0.12 mM) with ST2782 (10 mM) or with SAHA (3 mM) for 24 h in IGROV-1 cells. One representative
experiment of at least three is shown. B) IGROV-1/Pt1 cells were treated for 24 h with PTX (0.012 mM) or ST2782 (10 mM) alone or in combination. One
representative experiment of at least three is shown.
doi:10.1371/journal.pone.0029085.g006
reports the combination index values (CI) calculated according to ‘‘Chou and Talalay method’’. Cells were treated with different doses of ST2782 in
presence or absence of PTX (0.12 mM). G) IGROV-1 cells were exposed to SAHA (SH, 10 mM), alone or in combination with PTX for different times. H)
Comparison of effects of HDACi on acetylation of a-tubulin, histone H4 and p53 in IGROV-1 cells after 4 h exposure. a-tubulin is shown as a control of
protein loading.
doi:10.1371/journal.pone.0029085.g005
Table 1. Antitumor activity of PTX alone or in combination
with histone deacetylase inhibitors (ST2782, ST3595 or SAHA)
against the ovarian carcinoma model IGROV-1.
Drug
treatment
Dose
(mg/kg) Schedule TVI
a CR
b BWL
c
PTX 36 q7dx3 90 0/8 9
ST2782 20 qdx5d/wx3w 30 0/8 7
PTX+ST2782 98 0/8 9
PTX 24 q4dx4 90 2/8 5
ST3595 100 qdx5d/wx3w 49 0/8 9
PTX+ST3595 98 3/10 12
SAHA 100 qdx5d/wx3w 64 0/8 5
PTX+SAHA 87 1/8 22
aTumor volume inhibition (%) in treated vs control mice, determined one week
after the end of drug treatment.
bCR, complete response, i.e. disappearance of tumor lasting at least 10 days.
cBWL, body weight loss (%).
doi:10.1371/journal.pone.0029085.t001
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p53 mutant IGROV-1/Pt1 and A431 cell lines, could reflect loss
of p53 transcriptional function and marginal (if any) activation of
p21
WAF1/Cip1 (Figure 5C). Thus, the ST2782-induced down-
regulation of mutant p53 may have a marginal impact owing to
lack of its function. Again, p53 silencing in IGROV-1 cells caused
a lack of p21
WAF1/Cip1 up-regulation, an increase sensitivity to
single-agent treatment and an absence of synergistic interaction in
the combined treatment. The interpretation implicating p21
WAF1/
Cip1 upregulation as a protective event in response to taxane was
also consistent with the moderate synergism between SAHA and
PTX, because SAHA had not effect in the modulation of
p21
WAF1/Cip1 in paclitaxel-treated cells. Thus, the different profile
of protein acetylation induced by SAHA and novel HDACi used
in this study could account for the different cellular response to
their combination with PTX (Figure 5F). However, the pleiotropic
effects of HDACi do not allow a definitive explanation of the
observed synergistic interaction with antimicrotubule agents.
The sensitization of wild-type p53 cells in vitro to PTX by
ST3595 was confirmed in tumor xenograft models. The
enhancement of the PTX antitumor efficacy by ST3595 was
impressive in the osteosarcoma model resulting in complete tumor
regression in all treated animals, without evidence of disease at the
end of the experiment (after three months). These preclinical
findings may have therapeutic implications also considering the
use of nontoxic doses of PTX and the good tolerability of ST3595
following protracted oral administration.
In conclusion, given the current interest for combination
therapy with HDACi, the present study provides a basis for a
rational strategy to improve the taxane-based antitumor therapy.
Supporting Information
Figure S1 Dual parameter analysis of apoptosis induc-
tion and DNA content by flow-cytometry. Cells were treated
for different times with subtoxic (antiproliferative) concentrations
of ST2782 (10 mM) combined with PTX at IC50 (0.12 mM). At
each time, cells were fixed and processed as described in ‘Materials
and method’ section. Green fluorescence (y-axis): cleaved caspase
3 (CPP32); red fluorescence (x-axis): propidium iodide. The upper
quadrant represents cleaved CPP32-positive cells. In each panel
equivalent phases of the cell cycle are indicated on the basis of
DNA content by PI staining.
(TIF)
Table S1 Combination index values (CI) of the PTX/
ST2782 (or ST3595) combined treatment as a function of
cell lines p53 gene status.
(TIF)
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